Connect with us

Health

Canadian patients with lung disease still dying without access to only treatment

Published

on

Too many lives have been put at risk and lost to idiopathic pulmonary fibrosis (IPF) in Canada since the Canadian Pulmonary Fibrosis Foundation (CPFF) first took its fight for access to treatment to government policy.

This week, in advance of International Rare Disease Day on February 28th, Canadian IPF patients and caregivers are appealing again to their governments for urgent affordable universal access to Esbriet (pirfenidone), the first and only medicine approved in Canada to treat mild to moderate forms of IPF.

Esbriet has been proven to slow the progression of this rare, debilitating and ultimately fatal lung disease that scars the lungs so severely, patients are no longer able to breathe.

“When you have a disease that has a life expectancy of just a few years, the unfortunate reality is that these patients just can’t wait,” said Dr. Shane Shapera, Respirologist at Toronto General Hospital. “As it stands right now, I have two tiers of patients – those who have private insurance and can access treatment, and those without private insurance who cannot access treatment.

In actuality, IPF patients are running out of time, and sadly, many of them will likely die before they get a chance to start on therapy for their disease.”lung disease

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with no known cause, characterized predominantly by fibrosis (scarring) of the lungs. In patients with IPF, the lung tissue becomes scarred and over time, the scarring becomes thicker and more widespread, causing the lungs to lose their ability to transfer oxygen into the bloodstream.

The Canadian Pulmonary Fibrosis Foundation (CPFF) is a registered not-for-profit charitable organization established to provide support, hope and resources for those affected by pulmonary fibrosis.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health

Hundreds of Indonesian healthcare workers contract COVID-19 despite vaccination, dozens hospitalised

Published

on

JAKARTA: More than 350 Indonesian doctors and healthcare workers have contracted COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.

Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.

Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90 per cent in the district.

Designated as a priority group, Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.

Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association.

While the number of Indonesian healthcare workers dying from COVID-19 has decreased significantly – dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 – public health experts say the Java hospitalisations are cause for concern.

“The data shows they have the Delta variant so it is no surprise that the breakthrough infection is higher than before because as we know the majority of healthcare workers in Indonesia got Sinovac, and we still don’t know yet how effective it is in the real world against the Delta variant,” said Dicky Budiman, an epidemiologist from Australia’s Griffith University.

Continue Reading

Health

China’s Covid-19 vaccine flops in Singapore too

Published

on

New Delhi: In a major setback to Chinas Covid vaccines, Singapore is not counting its citizens who received Sinovac Biotech shots as being vaccinated against Covid-19 due to lack of data to show that the doses are effective against coronavirus, especially the Delta strain.

“We don’t really have a medical or scientific basis or have the data now to establish how effective Sinovac is in terms of infection and severe illnesses on Delta,” local media cited health minister Ong Ye Kung as saying at a press conference on Wednesday.

The decision comes close on the heels of serious doubts arising over Chinese vaccines in Indonesia as those who have received the shots are also contracting Covid-19 and infections are surging in the country.

The Delta variant is currently the dominant strain of Covid-19 in Singapore and was identified in the city state in May. Only people who have received the Moderna and Pfizer shots, are being considered as vaccinated in the official records.

Singapore had allowed some private clinics to offer the Sinovac shot, CoronaVac, from mid-June. Around 17,000 people are reported to have received one dose of CoronaVac.

Local media had also reported Singapore’s director of medical services saying last month that evidence from other countries showed people who had taken CoronaVac were still getting infected.

Most of the vaccines being used by Indonesia have also come from China’s Sinovac Biotech. Some health workers inoculated with Sinovac jabs have been hospitalized due to Covid-19. A few have even died despite being fully immunized, according to a report in Nikkei Asia.

The Indonesian Doctors Association says that of the 14 doctors who died from the virus between February and May, ten had been fully vaccinated with Sinovac, while the rest had been given one dose.

Although there is a serious problem with Chinese vaccines due to inadequate data to show their efficacy, some countries are being forced to opt for them because of the cute shortage of vaccines worldwide amid the devastating pandemic.

Continue Reading

Health

102 people qualify for S$451,000 in Covid-19 vaccine injury financial aid to date: Ong Ye Kung

Published

on

SINGAPORE — The authorities have approved S$451,000 worth of financial aid to people who had suffered serious side effects from Covid-19 vaccines in Singapore, Health Minister Ong Ye Kung said on Tuesday (July 6).

The payments have either been paid out or are being processed to 102 applicants under the Vaccine Injury Financial Assistance Programme (Vifap) introduced by the Government in January.

They were among a total of 292 applicants who had submitted a complete Vifap application as of June 25, Mr Ong said.

Of these, 159 did not meet the eligibility criteria and 31 applications are waiting to be reviewed by an independent clinical panel or pending more medical information from the applicant’s doctor.

Mr Ong was responding in a written answer to a parliamentary question filed by Ms He Ting Ru, Member of Parliament for Sengkang Group Representation Constituency, who had asked about the applications made and payments approved under the programme.

TODAY has asked the Ministry of Health (MOH) for details of these approved payouts.

Vifap provides three tiers of support to people assessed to be adversely affected by their Covid-19 inoculation.

The first is a one-time payout of S$2,000 for patients who need hospitalisation and medical intervention and who later recover.

The second is a payout of up to S$10,000 that will be given to those who were hospitalised and required care in a high dependency or intensive care unit, but later recover from the side effects caused by the vaccine.



Continue Reading

Trending